Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.
Saved in:
| Title: | Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. |
|---|---|
| Authors: | Sherman S; Department of Medical Oncology and., Sandusky ZM; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Russo D; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Zak D; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA., Nardone A; Department of Medical Oncology and., Friel D; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hermida-Prado F; Department of Medical Oncology and., Heraud C; Department of Medical Oncology and., Kuziel G; Department of Medical Oncology and., Verma A; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Gaglia G; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Kabraji S; Department of Medical Oncology and.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and., Nguyen QD; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Santagata S; Harvard Medical School, Boston, Massachusetts, USA.; Ludwig Center at Harvard and.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Fanning SW; Department of Cancer Biology, Loyola University Stritch School of Medicine, Maywood, Illinois, USA., Jeselsohn R; Department of Medical Oncology and.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Susan F. Smith Center for Women's Cancers and. |
| Source: | JCI insight [JCI Insight] 2025 May 06; Vol. 10 (12). Date of Electronic Publication: 2025 May 06 (Print Publication: 2025). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
